Zhejiang Cancer Hospital was issued “Qualification Certificate of Drug Clinical Trial Institution” (certificate number: 0043) by State Food and Drug Administration (SFDA) On October 24, 2005.The Division of Oncology was accredited. On September 25, 2013 and March 6, 2017, the institution successfully passed the re-qualification inspection conducted by China Food and Drug Administration (CFDA). The phase I trial ward in institution was founded in 2018.
The clinical trial institution is responsible for clinical trials of phase I, II, III and IV anti-cancer drug trials, in-vitro diagnostic reagent, medical devices trials and Investigator- Initiated clinical Trials (IIT). Since establishment, the institution has undertaken more than 500 clinical trials for Investigational New Drug (IND) and nearly 400 IIT, among which more than 150 are international multi-center clinical trials.
In our institution, more than 30 experienced and reputable experts took the role of principal investigators (PI) in clinical trials, and the number of PI is increasing steadily in each department. On the other hand, more than 300 medical personnel in various related fields of clinical trials have received GCP regulation and clinical trial technical training, so we have reserved a batch of excellent clinical researchers in institution.
The executive deputy director of the institution is Dr. Weizhen Xu.
For more information on the clinical trial, please email to firstname.lastname@example.org.
Last update: Mar. 2020